moatshark My

All holdings

Incyte

INCY

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$1.4bn
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$113.36
+20.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+9.0%Q3 ’24
+4.5%Q4 ’24
-12.3%Q1 ’25
+12.5%Q2 ’25
+24.5%Q3 ’25
+16.5%Q4 ’25
-4.7%Q1 ’26
+20.4%Q2 ’26
Q3 ’24: +9.0%; Q4 ’24: +4.5%; Q1 ’25: -12.3%; Q2 ’25: +12.5%; Q3 ’25: +24.5%; Q4 ’25: +16.5%; Q1 ’26: -4.7%; Q2 ’26: +20.4%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Incyte.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Incyte
Dodge & Cox0.7%$1.4bn$1.4bnTrimmed -2.4%31 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Incyte
Bought or soldFiling
15 Oct 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold2,642$112.71$298kForm 4
15 Sep 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold13,985$120.49$1.7mForm 4
15 Sep 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold9,233$120.50$1.1mForm 4
19 Aug 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold10,801$125.56$1.4mForm 4
12 Aug 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold10,803$120.04$1.3mForm 4
5 Aug 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold10,640$122.69$1.3mForm 4
5 Aug 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold2,207$123.99$274kForm 4
3 Aug 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold6,055$120.43$729kForm 4
31 Jul 2026Cagnoni Pablo JPresident, Global Head of R&D▼ Sold15,888$119.70$1.9mForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold14,661$119.46$1.8mForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold6,171$119.43$737kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold5,332$119.42$637kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold4,695$119.39$561kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold2,864$119.40$342kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold2,293$119.41$274kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold2,187$119.47$261kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold1,643$119.51$196kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold1,642$119.38$196kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold326$121.69$40kForm 4
31 Jul 2026Mayes Patrick AEVP & Chief Scientific Officer▼ Sold85$122.19$10kForm 4

About the company

Sector
Health care · Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
203m at 21 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$355m2013
$754m2015
$1.5bn2017
$2.2bn2019
$3.0bn2021
$3.7bn2023
$5.1bn2025
2013: $355m; 2014: $511m; 2015: $754m; 2016: $1.1bn; 2017: $1.5bn; 2018: $1.9bn; 2019: $2.2bn; 2020: $2.7bn; 2021: $3.0bn; 2022: $3.4bn; 2023: $3.7bn; 2024: $4.2bn; 2025: $5.1bn
Incyte revenue and net income by year
YearRevenueNet income
2025$5.1bn$1.3bn
2024$4.2bn$32.6m
2023$3.7bn$598m
2022$3.4bn$341m
2021$3.0bn$949m
2020$2.7bn−$296m
2019$2.2bn$447m
2018$1.9bn$109m
2017$1.5bn−$313m
2016$1.1bn$104m
2015$754m–
2014$511m–
2013$355m–

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Incyte, from their latest N-PORT filings.

Funds holding Incyte
Dodge & Cox Global Stock FundDodge & Cox0.3%$43.4m30 Jun 2026